Fluindione

BLOOD AND BLOOD FORMING ORGANS

Key facts

Fluindione is a drug catalogued in DrugCentral. DrugCentral lists 1 molecular target, including Alox5.

• Molecular targets: Alox5 (1 listed in DrugCentral).
• ATC code: B01AA12 (Vitamin K antagonists).
• Molecular formula: C15H9FO2; molecular weight 240.23 g/mol.

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Arachidonate 5-lipoxygenase	Alox5	unknown	IC50 5.02

ATC classification

ATC code	Therapeutic hierarchy
B01AA12	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Vitamin K antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
International normalised ratio increased	1664.7
Drug interaction	878.1
Acute kidney injury	867.1
Shock haemorrhagic	470.8
Haematoma	395.2
Hyperkalaemia	374.6
Cerebral haematoma	372.3
Melaena	273.2
Anaemia	265.0
Bradycardia	219.4
Subdural haematoma	187.9
Lactic acidosis	174.3

Chemical structure

• Molecular formula: C₁₅H₉FO₂
• Molecular weight: 240.23 g/mol
• CAS number: 957-56-2
• InChIKey: NASXCEITKQITLD-UHFFFAOYSA-N
• PubChem CID: 68942

FC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Fluindione work?

Its molecular targets in DrugCentral include Alox5.

What is the chemical formula of Fluindione?

Fluindione has the molecular formula C15H9FO2 and a molecular weight of 240.23 g/mol.

Sources

• DrugCentral drug card 1194 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL24924 — compound record and bioactivity
• PubChem CID 68942 — chemical identifiers
• DrugBank DB13136 — drug record
• FDA UNII EQ35YMS20Q — substance identity
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.